Bezlotoxumab ( DrugBank: Bezlotoxumab )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	1
97	潰瘍性大腸炎	1

96. クローン病

---

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04626947 (ClinicalTrials.gov)	October 30, 2021	29/9/2020	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).	Inflammatory Bowel Diseases;Ulcerative Colitis;Crohn Disease;C. Diff. Infections	Biological: Bezlotoxumab	David Binion, MD	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	50	Phase 4	United States

97. 潰瘍性大腸炎

---

臨床試験数 : 2,527 /  薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04626947 (ClinicalTrials.gov)	October 30, 2021	29/9/2020	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).	Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).	Inflammatory Bowel Diseases;Ulcerative Colitis;Crohn Disease;C. Diff. Infections	Biological: Bezlotoxumab	David Binion, MD	Merck Sharp & Dohme Corp.	Recruiting	18 Years	N/A	All	50	Phase 4	United States